| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts |
| 06 Nov 2026 |
8-K: Regulation FD Disclosure
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis |
| 01 Oct 2026 |
Form 4: Reinke Kristin Marie K, Director
Granted 48,368 Stock Options (right to buy) |
| 01 Oct 2026 |
Form 3: Reinke Kristin Marie K, Director
No securities owned |
| 01 Oct 2026 | SCHEDULE 13D/A |
| 30 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., September 30, 2026 — Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where sh... |
| 13 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 | SCHEDULE 13G |
| 13 Jul 2026 |
Form 4: Perceptive Advisors Llc, Director and 3 others
Received 20,706 shares as a grant or award |
| 29 Jun 2026 | SCHEDULE 13G |
| 29 Jun 2026 | SCHEDULE 13D |
| 25 Jun 2026 | SCHEDULE 13D |
| 24 Jun 2026 |
Form 4: Hrtg GPE, Llc, 10% owner and 4 others
Bought 3,125,000 shares ($50M) |
| 24 Jun 2026 | Form 3/A: Hrtg GPE, Llc, 10% owner and 4 others |
| 24 Jun 2026 |
Form 4: Berns Paul L, Director
Bought 1,250,000 shares ($20M) |
Loading...